

**Table S2: Strains used in this study**

<b>Strain</b>	<b>Genotype<sup>a</sup></b>	<b>Source/Reference<sup>b</sup></b>
Dh5a(lpir)	<i>F- hsdR17 deoR recA1 endA1 phoA supE44 thi-1 gyrA96 relA1 Δ(lacZYA-argF)U169 ø80dlacZΔM15 λpir</i>	Laboratory strain
MG1655	<i>rph1 lvG rfb-50</i>	(1)
TB28	MG1655 <i>ΔlacZYA::ftr</i>	(2)
TB10	MG1655 <i>λΔcro-bio nad::Tn10</i>	(3)
EMF25	TB10 <i>ΔyejM::kan</i> + pEMF17	(λRed)/This study
EMF27	TB28 <i>ΔyejM::kan</i> + pEMF17	P1(EMF25) X TB28 + pEMF17/This study
EMF30	MG1655 <i>ΔyejM::kan</i> + pPR111	P1(EMF25) X MG1655 + pPR111/This study
JLB45	<i>F- hsdR17 deoR recA1 endA1 phoA supE44 thi-1 gyrA96 relA1 Δ(lacZYA-argF)U169 ø80dlacZΔM15 λpir ΔlysAR&lt;&gt;tetAR-Psyn135::cl</i>	Derivative of strain from de Boer lab (4)
EMF37	MG1655 <i>ΔyejM::kan</i> + pEMF20	P1(EMF25) X MG1655 + pEMF10/This study
EMF40	MG1655 <i>ΔyejM::kan</i> , amplification containing <i>lpxC</i> ( <i>viaO-yjgX</i> )	This study
EMF41	MG1655 <i>ΔyejM::kan</i> , <i>lpxC</i> (V37G), <i>aspC</i> (A371A)	This study
EMF42	MG1655 <i>ΔyejM::kan</i> has two amplified regions ( <i>ykfC-rrlE</i> , <i>hemG-yhcF</i> ), one of which contains <i>lpxC</i>	This study
EMF43	MG1655 <i>ΔyejM::kan</i> A -> T mutation upstream of <i>gspH</i> , amplification containing <i>lpxC</i> ( <i>hokE-yjgX</i> )	This study
EMF44	MG1655 <i>ΔyejM::kan</i> has two amplified regions, ( <i>hokE-nmpC</i> , <i>ykfC-mokC</i> ) one of which contains <i>lpxC</i>	This study
EMF45	MG1655 <i>ΔyejM::kan</i> , <i>lapB</i> (H181R)	This study
EMF46	MG1655 <i>ΔyejM::kan</i> , C-> A point mutant upstream of <i>lapAB</i> operon	This study

EMF47	MG1655 $\Delta yejM::kan$ , <i>lpxC(L114Q)</i>	This study
EMF48	MG1655 $\Delta yejM::kan$ , <i>lapA(36QSTOP)</i>	This study
EMF49	MG1655 $\Delta yejM::kan$ , Amplification ( <i>yejO-yecF</i> )	This study
EMF50	MG1655 $\Delta yejM::kan$ , Amplification ( <i>yejO-yecF</i> )	This study
EMF51	MG1655 $\Delta yejM::kan$ , Amplification contains <i>lpxC</i>	This study
EMF68	TB10 $\Delta yejM_{(1-191)}::kan$ + pEMF17	( $\lambda$ Red)/This study
EMF69	TB28 $\Delta yejM_{(1-191)}::kan$ + pEMF17	P1(EMF68) X TB28 + pEMF17/This study

<sup>a</sup> The kanamycin resistance cassette (*kan*) is flanked by *frt* sequences for removal by FLP recombinase

<sup>b</sup> Strains generate by P1 transduction are described as follows: P1(donor strain) X recipient strain (See Methods for details)

1. M. Guyer, R. R. Reed, J. Steitz, K. Low, in *Cold Spring Harbor symposia on quantitative biology*. (Cold Spring Harbor Laboratory Press, 1981), vol. 45, pp. 135-140.
2. T. G. Bernhardt, P. A. De Boer, Screening for synthetic lethal mutants in *Escherichia coli* and identification of EnvC (YibP) as a periplasmic septal ring factor with murein hydrolase activity. *Molecular microbiology* **52**, 1255-1269 (2004).
3. J. E. Johnson, L. L. Lackner, C. A. Hale, P. A. De Boer, ZipA is required for targeting of DMinC/DicB, but not DMinC/MinD, complexes to septal ring assemblies in *Escherichia coli*. *Journal of bacteriology* **186**, 2418-2429 (2004).
4. B. Liu, L. Persons, L. Lee, P. A. de Boer, Roles for both FtsA and the FtsBLQ subcomplex in FtsN-stimulated cell constriction in *Escherichia coli*. *Molecular microbiology* **95**, 945-970 (2015).